Meifen Zhang

2.2k citations
84 papers · 1.2k indexed · h-index 17

Meifen Zhang

80 papers receiving 1.2k citations

Peers

Meifen Zhang
Comparison fields: 5 of 104
  • Ophthalmology 480
  • Immunology 355
  • Rheumatology 226
  • Oncology 244
  • Cancer Research 97
Replace Rachel C. Brennan with:
Rachel C. Brennan United States
Irene Scheimberg United Kingdom
Ryan Webb United States
Diana Abbott United States
Xiaoyan Li China
Başak Yalçın Türkiye
Ahmed Mousa Saudi Arabia
Natasha Singh United Kingdom
Benjamin W. Darbro United States
Rossella Talotta Italy
Meifen Zhang relative to Rachel C. Brennan United States Rachel C. Brennan's profile →
Citations per field
00.5×8.1×
Rachel C. Brennan · 1×
Citations per year

Countries citing papers authored by Meifen Zhang

Since Specialization
Citations

This map shows the geographic impact of Meifen Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meifen Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meifen Zhang more than expected).

Fields of papers citing papers by Meifen Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meifen Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meifen Zhang. The network helps show where Meifen Zhang may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Meifen Zhang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Meifen Zhang Line = papers co-authored together Meifen Zhang links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20251
2 20250
3 20242
4 20232
5 20234
6 20233
7 20230
8 20221
9 20221
10 20225
11 202114
12 202017
13 20207
14
[Association between optical coherence tomography findings and visual acuity of Behcet's disease-associated uveitis patients during remission stage].
20151
15 20147
16 201397
17 200338
18 2002207
19 200137
20 20017

About Meifen Zhang

Meifen Zhang is a scholar working on Ophthalmology, Rheumatology and Neurology, having authored 84 papers that have together received 1.2k indexed citations. Recurring topics across this work include Ocular Diseases and Behçet’s Syndrome (43 papers), Retinal and Optic Conditions (27 papers), Retinal Diseases and Treatments (18 papers), CNS Lymphoma Diagnosis and Treatment (12 papers), Systemic Lupus Erythematosus Research (12 papers), Lymphoma Diagnosis and Treatment (12 papers), Glaucoma and retinal disorders (7 papers) and Ocular Infections and Treatments (4 papers). The work is most often cited by research in Ophthalmology (480 citations), Immunology (355 citations) and Rheumatology (226 citations). Meifen Zhang has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Igal Gery, Chan Zhao, Stephen J. Kim, Charles E. Egwuagu, Cheng‐Rong Yu, Rashid M. Mahdi, Chi‐Chao Chan, Eric F. Wawrousek, Fei Gao and Wei-Yan Liu. Their work appears in journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Frontiers in Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026